(Q54619824)

English

Stability of HER2-positive status in breast carcinoma: a comparison between primary and paired metastatic tumors with regard to the possible impact of intervening trastuzumab treatment

scientific article published on January 14, 2011

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21239403

Stability of HER2-positive status in breast carcinoma: a comparison between primary and paired metastatic tumors with regard to the possible impact of intervening trastuzumab treatment (English)

1 reference

10.1093/ANNONC/MDQ623

https://api.crossref.org/works/10.1093/ANNONC/MDQ623

22 November 2024

breast carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Ana Maria Gonzalez-Angulo

4

object named as

A M Gonzalez-Angulo

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21239403

author name string

C. Xiao

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21239403

22 November 2024

Y. Gong

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21239403

22 November 2024

E. Y. Han

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21239403

22 November 2024

N. Sneige

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21239403

22 November 2024

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21239403

22 November 2024

publication date

14 January 2011

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21239403

full work available at URL

http://www.annalsofoncology.org/article/S0923753419384297/pdf

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21239403

22 November 2024

https://api.elsevier.com/content/article/PII:S0923753419384297?httpAccept=text/xml

1 reference

10.1093/ANNONC/MDQ623

https://api.crossref.org/works/10.1093/ANNONC/MDQ623

22 November 2024

https://api.elsevier.com/content/article/PII:S0923753419384297?httpAccept=text/plain

1 reference

10.1093/ANNONC/MDQ623

https://api.crossref.org/works/10.1093/ANNONC/MDQ623

22 November 2024

http://academic.oup.com/annonc/article-pdf/22/7/1547/458027/mdq623.pdf

1 reference

10.1093/ANNONC/MDQ623

https://api.crossref.org/works/10.1093/ANNONC/MDQ623

22 November 2024

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21239403

22

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21239403

7

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21239403

1547-1553

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21239403

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

1

1 reference

10.1093/ANNONC/MDQ623

https://api.crossref.org/works/10.1093/ANNONC/MDQ623

22 November 2024

Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review

2

1 reference

10.1093/ANNONC/MDQ623

https://api.crossref.org/works/10.1093/ANNONC/MDQ623

22 November 2024

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

3

1 reference

10.1093/ANNONC/MDQ623

https://api.crossref.org/works/10.1093/ANNONC/MDQ623

22 November 2024

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

4

1 reference

10.1093/ANNONC/MDQ623

https://api.crossref.org/works/10.1093/ANNONC/MDQ623

22 November 2024

Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites

5

1 reference

10.1093/ANNONC/MDQ623

https://api.crossref.org/works/10.1093/ANNONC/MDQ623

22 November 2024

Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma

6

1 reference

10.1093/ANNONC/MDQ623

https://api.crossref.org/works/10.1093/ANNONC/MDQ623

22 November 2024

Assessment of Her-2/neu overexpression in primary breast cancers and their metastatic lesions: an immunohistochemical study

7

1 reference

10.1093/ANNONC/MDQ623

https://api.crossref.org/works/10.1093/ANNONC/MDQ623

22 November 2024

Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer

8

1 reference

10.1093/ANNONC/MDQ623

https://api.crossref.org/works/10.1093/ANNONC/MDQ623

22 November 2024

HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process

9

1 reference

10.1093/ANNONC/MDQ623

https://api.crossref.org/works/10.1093/ANNONC/MDQ623

22 November 2024

HER-2/neu genotype of breast cancer may change in bone metastasis

10

1 reference

10.1093/ANNONC/MDQ623

https://api.crossref.org/works/10.1093/ANNONC/MDQ623

22 November 2024

HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy

11

1 reference

10.1093/ANNONC/MDQ623

https://api.crossref.org/works/10.1093/ANNONC/MDQ623

22 November 2024

HER-2/neu expression in primary and metastatic breast cancer

12

1 reference

10.1093/ANNONC/MDQ623

https://api.crossref.org/works/10.1093/ANNONC/MDQ623

22 November 2024

Trastuzumab plus tamoxifen: anti-proliferative and molecular interactions in breast carcinoma.

13

1 reference

10.1093/ANNONC/MDQ623

https://api.crossref.org/works/10.1093/ANNONC/MDQ623

22 November 2024

Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate

14

1 reference

10.1093/ANNONC/MDQ623

https://api.crossref.org/works/10.1093/ANNONC/MDQ623

22 November 2024

Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy

15

1 reference

10.1093/ANNONC/MDQ623

https://api.crossref.org/works/10.1093/ANNONC/MDQ623

22 November 2024

Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer

16

1 reference

10.1093/ANNONC/MDQ623

https://api.crossref.org/works/10.1093/ANNONC/MDQ623

22 November 2024

Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study.

17

1 reference

10.1093/ANNONC/MDQ623

https://api.crossref.org/works/10.1093/ANNONC/MDQ623

22 November 2024

Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer

18

1 reference

10.1093/ANNONC/MDQ623

https://api.crossref.org/works/10.1093/ANNONC/MDQ623

22 November 2024

Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer

19

1 reference

10.1093/ANNONC/MDQ623

https://api.crossref.org/works/10.1093/ANNONC/MDQ623

22 November 2024

Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes

20

1 reference

10.1093/ANNONC/MDQ623

https://api.crossref.org/works/10.1093/ANNONC/MDQ623

22 November 2024

A case of metastatic breast cancer with outgrowth of HER2-negative cells after eradication of HER2-positive cells by humanized anti-HER2 monoclonal antibody (trastuzumab) combined with docetaxel

21

1 reference

10.1093/ANNONC/MDQ623

https://api.crossref.org/works/10.1093/ANNONC/MDQ623

22 November 2024

Trastuzumab administration associated with change in HER2 status

22

1 reference

10.1093/ANNONC/MDQ623

https://api.crossref.org/works/10.1093/ANNONC/MDQ623

22 November 2024

Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer

23

1 reference

10.1093/ANNONC/MDQ623

https://api.crossref.org/works/10.1093/ANNONC/MDQ623

22 November 2024

Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy

24

1 reference

10.1093/ANNONC/MDQ623

https://api.crossref.org/works/10.1093/ANNONC/MDQ623

22 November 2024

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

25

1 reference

10.1093/ANNONC/MDQ623

https://api.crossref.org/works/10.1093/ANNONC/MDQ623

22 November 2024

Optimal fixation conditions for immunocytochemical analysis of estrogen receptor in cytologic specimens of breast carcinoma

26

1 reference

10.1093/ANNONC/MDQ623

https://api.crossref.org/works/10.1093/ANNONC/MDQ623

22 November 2024

The Measurement of Observer Agreement for Categorical Data

27

1 reference

10.1093/ANNONC/MDQ623

https://api.crossref.org/works/10.1093/ANNONC/MDQ623

22 November 2024

Change of HER-2/neu status in a subset of distant metastases from breast carcinomas

28

1 reference

10.1093/ANNONC/MDQ623

https://api.crossref.org/works/10.1093/ANNONC/MDQ623

22 November 2024

HER-2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy

29

1 reference

10.1093/ANNONC/MDQ623

https://api.crossref.org/works/10.1093/ANNONC/MDQ623

22 November 2024

Marked Intratumoral Heterogeneity of the Proto-Oncogene Her-2/neu Determined by Three Different Detection Systems

31

1 reference

10.1093/ANNONC/MDQ623

https://api.crossref.org/works/10.1093/ANNONC/MDQ623

22 November 2024

Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study

33

1 reference

10.1093/ANNONC/MDQ623

https://api.crossref.org/works/10.1093/ANNONC/MDQ623

22 November 2024

Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831

34

1 reference

10.1093/ANNONC/MDQ623

https://api.crossref.org/works/10.1093/ANNONC/MDQ623

22 November 2024

Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message

35

1 reference

10.1093/ANNONC/MDQ623

https://api.crossref.org/works/10.1093/ANNONC/MDQ623

22 November 2024

Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast cancer cells to estrogen

36

1 reference

10.1093/ANNONC/MDQ623

https://api.crossref.org/works/10.1093/ANNONC/MDQ623

22 November 2024

Identifiers

10.1093/ANNONC/MDQ623

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21239403

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21239403

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54619824&oldid=2278203158"